Azitra, Inc. (AZTR)

Azitra, Inc. (AZTR) Healthcare & Pipeline Overview

Azitra, Inc. is a pre-clinical biopharmaceutical company innovating dermatological treatments through engineered proteins and live biotherapeutic products. Focused on conditions like Netherton syndrome, EGFRI-induced rash, and ichthyosis vulgaris, the company leverages novel approaches to address significant unmet medical needs in skin health, positioning itself in the specialized biotechnology sector.

What Is the Investment Thesis for AZTR?

Azitra, Inc. presents a research-stage investment profile centered on its innovative pre-clinical pipeline targeting dermatological conditions with high unmet medical needs. The company's strategy leverages engineered proteins and live biotherapeutic products, specifically focusing on the skin microbiome, to develop therapies for Netherton syndrome (ATR-12), EGFRI-induced rash (ATR-04), and ichthyosis vulgaris (ATR-01). This novel approach differentiates Azitra from conventional treatments, potentially offering disease-modifying solutions rather than just symptomatic relief. Key value drivers include the potential for breakthrough therapies in orphan diseases like Netherton syndrome, where current options are limited. The company's pre-clinical stage signifies significant future catalysts tied to advancing its candidates into clinical trials and demonstrating efficacy and safety. However, as a pre-clinical biopharmaceutical entity, Azitra faces inherent risks associated with drug development, including the high probability of clinical trial failures, extensive regulatory hurdles, and the substantial capital requirements for research and development. Investors should monitor progress through the various phases of clinical development, potential partnerships, and future financing activities as critical indicators of the company's trajectory and ability to mitigate these risks.

Based on FMP financials and quantitative analysis

AZTR Key Highlights

• Market Capitalization: $0.00 billion, reflecting its early-stage development and pre-revenue status.
• Beta: -1.28, indicating a historical inverse correlation to broader market movements, though this can be volatile for early-stage biotech.
• Dividend Yield: None, as the company is a pre-clinical biopharmaceutical entity focused on R&D investment.
• Employee Count: 12 employees, underscoring its lean operational structure typical of a focused biotech startup.
• Pipeline Focus: Three distinct pre-clinical candidates (ATR-12, ATR-04, ATR-01) targeting specific dermatological conditions.

Who Are AZTR's Competitors?

AZTR is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are AZTR's Key Strengths?

• Novel therapeutic approach utilizing engineered proteins and live biotherapeutic products for skin diseases.
• Pipeline targets specific dermatological conditions with high unmet medical needs.
• Focus on the skin microbiome represents a cutting-edge area in dermatology.
• Experienced leadership in Francisco D. Salva, managing a focused team of 12 employees.

What Are AZTR's Weaknesses?

• Pre-clinical stage company with no products currently on the market or in late-stage clinical trials.
• Significant capital requirements for future clinical development and regulatory processes.
• Small employee base (12 employees) may limit the scope and speed of multiple parallel development programs.
• Lack of revenue generation due to its early development stage.

What Could Drive AZTR Stock Higher?

• Initiation of first-in-human (Phase 1) clinical trials for ATR-12, ATR-04, or ATR-01, validating the safety profile of its lead candidates.
• Announcement of successful pre-clinical data readouts for any of its pipeline candidates, supporting advancement to clinical stages.
• Formation of strategic partnerships or licensing agreements with larger pharmaceutical companies, providing non-dilutive funding and development expertise.
• Continued research and development efforts to expand the understanding of the skin microbiome and identify new therapeutic targets.

What Are the Key Risks for AZTR?

• Financial-distress signal — its Altman Z-Score of -9.97 sits in the distress zone (elevated bankruptcy risk).
• Weak fundamentals — a Piotroski F-Score of 2/9 flags soft profitability, leverage or efficiency.
• High risk of clinical trial failures, as most drug candidates do not successfully complete all phases of development.
• Significant regulatory hurdles and lengthy approval processes inherent to novel biopharmaceutical products.
• Substantial capital requirements to fund pre-clinical and future clinical development, potentially leading to future dilutive financing.
• Intense competition from established pharmaceutical companies and other biotechnology firms in the dermatology space.
• Dependence on the successful development and commercialization of a limited number of pipeline candidates.

What Are the Growth Opportunities for AZTR?

• Growth opportunity 1: Advancement of ATR-12 for Netherton Syndrome. Netherton syndrome is a rare, severe genetic disorder with significant unmet medical needs, as current treatments primarily offer symptomatic relief. Azitra's ATR-12, a genetically modified strain of S. epidermidis, aims to provide a targeted therapeutic solution by addressing the underlying skin barrier dysfunction. Successful progression of ATR-12 through pre-clinical development and into human clinical trials would represent a major milestone. The market for orphan drugs, while numerically smaller, often commands premium pricing due to the severity of the conditions and lack of alternatives, offering substantial revenue potential upon regulatory approval. This could position Azitra as a leader in treating rare dermatological conditions.
• Growth opportunity 2: Development of ATR-04 for EGFRI-induced rash. The papulopustular rash is a common and debilitating side effect for cancer patients undergoing epidermal growth factor receptor inhibitor (EGFRI) therapy, significantly impacting their quality of life and treatment adherence. Azitra's ATR-04, another modified S. epidermidis strain, is designed to alleviate this specific dermatological toxicity. The growing use of EGFRI therapies in oncology suggests a substantial patient population that could benefit from an effective preventative or therapeutic solution for this rash. Successful clinical development and market entry for ATR-04 would tap into a recurring need within oncology supportive care, offering a clear value proposition to both patients and healthcare providers.
• Growth opportunity 3: Progress of ATR-01 for Ichthyosis Vulgaris. Ichthyosis vulgaris is a common genetic skin disorder caused by a deficiency in filaggrin, leading to dry, scaly skin. Azitra's ATR-01, an engineered recombinant human filaggrin protein, aims to directly address this deficiency by restoring the essential protein for skin barrier function. Given the prevalence of ichthyosis vulgaris, a successful therapy that effectively restores skin barrier function could address a large patient population currently relying on emollients and symptomatic treatments. Achieving positive clinical outcomes and regulatory approval for ATR-01 would position Azitra to capture a significant share of the market for chronic dry skin conditions, particularly those with a genetic basis.
• Growth opportunity 4: Expansion into broader skin microbiome therapeutics. Azitra's foundational expertise in leveraging the skin microbiome for therapeutic purposes extends beyond its current pipeline. The understanding of the skin microbiome's role in various dermatological and systemic conditions is rapidly evolving, presenting numerous opportunities for future product development. This includes potential applications in atopic dermatitis, acne, psoriasis, and wound healing. By establishing a robust platform for engineered live biotherapeutic products, Azitra could expand its pipeline to address a wider array of skin conditions, attracting further investment and partnerships. This strategic growth path could unlock significant long-term value by diversifying its therapeutic portfolio and market reach.
• Growth opportunity 5: Strategic partnerships and licensing agreements. As a pre-clinical biopharmaceutical company, Azitra's ability to advance its pipeline through costly and complex clinical trials can be significantly enhanced through strategic collaborations. Partnering with larger pharmaceutical companies could provide access to substantial funding, extensive clinical development expertise, and established commercialization infrastructure. Licensing agreements for specific pipeline candidates or its underlying technology platform could accelerate development, reduce financial risk, and provide non-dilutive capital. Such partnerships would validate Azitra's scientific approach and potentially expedite the delivery of its innovative therapies to patients, representing a critical growth catalyst for an early-stage biotech firm.

What Opportunities Does AZTR Have?

• Potential for breakthrough therapies in orphan diseases like Netherton syndrome.
• Expansion of its platform to address a broader range of dermatological conditions beyond the current pipeline.
• Strategic partnerships or licensing agreements to accelerate development and mitigate financial risk.
• Growing understanding and acceptance of microbiome-based therapeutics in medicine.

What Threats Does AZTR Face?

• High risk of clinical trial failures, common in biopharmaceutical development.
• Intense regulatory hurdles and lengthy approval processes for novel drugs.
• Competition from larger pharmaceutical companies or other biotech firms developing similar or alternative treatments.
• Dependence on successful financing rounds to fund ongoing research and development activities.

What Are AZTR's Competitive Advantages?

• Proprietary technology platform leveraging engineered proteins and live biotherapeutic products for skin conditions.
• Focus on the skin microbiome, a novel and emerging area for dermatological therapy.
• Targeting of specific, high-unmet-need dermatological conditions with potentially disease-modifying treatments.
• Intellectual property surrounding its genetically modified S. epidermidis strains and recombinant human filaggrin protein.
• Early-mover advantage in developing specific live biotherapeutic products for defined dermatological indications.

What Does AZTR Do?

Azitra, Inc., founded in 2014 and headquartered in Branford, Connecticut, is a pre-clinical biopharmaceutical company dedicated to developing precise and innovative treatments for a range of dermatological conditions. The company's core strategy revolves around harnessing the power of engineered proteins and live biotherapeutic products to address skin diseases at their root cause. This novel approach differentiates Azitra from traditional dermatological treatments, which often focus on symptomatic relief rather than underlying mechanisms. Azitra's pipeline is structured around several key therapeutic candidates, each designed to tackle specific and often severe skin disorders. One prominent candidate is ATR-12, a genetically modified strain of Staphylococcus epidermidis. This live biotherapeutic product is specifically intended for the treatment of Netherton syndrome, a rare and debilitating genetic skin disorder characterized by severe skin barrier dysfunction and chronic inflammation. By introducing a modified S. epidermidis, Azitra aims to restore critical skin functions and alleviate the severe symptoms associated with Netherton syndrome. Another significant program is ATR-04, which also utilizes a modified S. epidermidis strain. ATR-04 is being developed to mitigate the papulopustular rash, a common and distressing side effect experienced by cancer patients undergoing epidermal growth factor receptor inhibitor (EGFRI) therapy. This condition significantly impacts patients' quality of life, and ATR-04 seeks to offer a targeted solution to this treatment-induced dermatological toxicity. Furthermore, Azitra's pipeline includes ATR-01, an engineered recombinant human filaggrin protein. This therapeutic candidate is under development for the treatment of ichthyosis vulgaris, a widespread genetic skin disorder characterized by dry, scaly skin due to a deficiency in filaggrin, a protein crucial for skin barrier function. By delivering a functional filaggrin protein, ATR-01 aims to restore the skin's natural barrier and improve the condition of affected individuals. Azitra's focus on the skin microbiome and protein engineering represents a forward-thinking approach in dermatology, aiming to provide targeted, disease-modifying therapies for conditions with significant unmet medical needs.

What Products and Services Does AZTR Offer?

• Develops precise treatments for dermatological conditions.
• Utilizes engineered proteins as therapeutic agents.
• Employs live biotherapeutic products, specifically modified S. epidermidis strains.
• Focuses on Netherton syndrome with its ATR-12 candidate.
• Addresses papulopustular rash in cancer patients with ATR-04.
• Targets ichthyosis vulgaris with its engineered recombinant human filaggrin protein, ATR-01.
• Operates as a pre-clinical stage biopharmaceutical company.
• Headquartered in Branford, Connecticut, with 12 employees.

How Does AZTR Make Money?

• Focuses on research and development of novel biopharmaceutical candidates for dermatological diseases.
• Aims to generate revenue through the successful development, regulatory approval, and commercialization of its pipeline products.
• Potential for out-licensing agreements or strategic partnerships with larger pharmaceutical companies for clinical development and commercialization.
• Relies on venture capital, public offerings, or other financing mechanisms to fund its pre-clinical and future clinical operations.

What Industry Does AZTR Operate In?

Azitra, Inc. operates within the highly specialized and innovative biotechnology industry, specifically focusing on dermatological therapeutics. This sector is characterized by extensive research and development, long development cycles, and significant regulatory oversight. The broader dermatology market is experiencing growth driven by an increasing prevalence of skin disorders, greater awareness, and advancements in treatment modalities. Azitra's positioning is unique due to its emphasis on the skin microbiome and engineered proteins, a frontier area in dermatology that seeks to address underlying disease mechanisms rather than just symptoms. While the market for traditional topical and systemic dermatological drugs is competitive, Azitra aims to carve out niche markets by targeting conditions with high unmet medical needs, such as Netherton syndrome and ichthyosis vulgaris. The competitive landscape includes established pharmaceutical companies with broad dermatology portfolios and other biotech firms exploring novel therapeutic approaches, including gene therapies and biologics. Azitra's pre-clinical stage means it is currently focused on scientific validation and early-stage development, positioning it as a potential disruptor in specific dermatological segments.

Who Are AZTR's Key Customers?

• Patients suffering from Netherton syndrome, a rare genetic skin disorder.
• Cancer patients experiencing papulopustular rash as a side effect of EGFRI therapy.
• Individuals diagnosed with ichthyosis vulgaris, a common genetic dry skin condition.
• Healthcare providers (dermatologists, oncologists) seeking novel and effective treatments for these specific conditions.
• Potential pharmaceutical partners interested in licensing or co-developing innovative dermatological therapies.

How Azitra, Inc. Is Valued

Azitra, Inc. carries a market capitalization of $1.64M, placing it in the micro-cap category. Relative to its peer group, AZTR's quantitative score of 29/100 is below the peer average of 76/100.

Company Profile

Azitra, Inc. operates in the Biotechnology industry within the Healthcare sector. It is headquartered in Branford, US. The company is led by CEO Francisco D. Salva. AZTR has traded publicly since 2023.

Key Financial Metrics

Return on assets is -97.4%, showing how much profit it generates from its asset base. A current ratio of 6.94 indicates the company holds enough short-term assets to cover its near-term obligations.

F-Score 2/9Financial Health

Azitra, Inc.'s Piotroski F-Score is 2/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of -9.97 places it in the distress zone, a signal of elevated financial risk.

FY2026 estForward Outlook

Wall Street analysts project Azitra, Inc. revenue of about $0 for fiscal 2026, with EPS near $-0.26.

Net buyingInsider Activity

Over the past six months, Azitra, Inc. insiders filed 6 SEC Form 4 transactions — 0 sales and 6 purchases. On net that is roughly 8.4M shares acquired (about $1.1M) — insiders putting money in tends to read as conviction.

AZTR Financials

AZTR Latest News

AZTR Analyst Consensus

AZTR MoonshotScore

Azitra, Inc. Healthcare Stock: Key Questions Answered

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources